IRWD

#2436
Ironwood Pharmaceuticals, Inc. - Class A
3.42
-3.66%
セクター:
ベース:
利益通貨:
日中レンジ
3.42
3.42
1年のレンジ
0.53
5.78
1日の変化
-3.66%
月次変化
-33.33%
6か月変化
+167.19%
1年の変化
+107.27%
以前の終値
3.55
Open
3.42
Bid
Ask
Low
3.42
High
3.42
ボリューム
112
Open full chart

Financials

Overview 明細書 Statistics Dividends
Quarterly Annual
  • Market Capitalization 554.78 M
  • Employee 253
  • Founded 1998
  • CEO N/A
  • Website www.ironwoodpharma.com
  • Headquarter Delaware, United States
  • FIGI BBG000GBZ3J2
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
22.47
Price to sales ratio
—
Dividends per share
—
Dividend yield %
—

Ironwood Pharmaceuticals Inc - Class A

Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea. By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide.

ニュース